A share price of Keros Therapeutics Inc [KROS] is currently trading at $14.32, up 2.95%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The KROS shares have gain 7.35% over the last week, with a monthly amount drifted -4.79%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Keros Therapeutics Inc [NASDAQ: KROS] stock has seen the most recent analyst activity on June 10, 2025, when BofA Securities downgraded its rating to a Neutral but kept the price target unchanged to $18 for it. Previously, Cantor Fitzgerald downgraded its rating to Neutral on January 21, 2025. On January 17, 2025, downgrade downgraded it’s rating to Neutral but maintained its price target of $15 on the stock. Oppenheimer reiterated its Outperform rating and decreased its price target to $63 on December 16, 2024. Guggenheim downgraded its rating to a Neutral. H.C. Wainwright reiterated a Buy rating for this stock on December 13, 2024, and downed its price target to $47. In a note dated December 12, 2024, William Blair downgraded an Mkt Perform rating on this stock.
Keros Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $9.12 and $72.37. Currently, Wall Street analysts expect the stock to reach $102.6 within the next 12 months. Keros Therapeutics Inc [NASDAQ: KROS] shares were valued at $14.32 at the most recent close of the market. An investor can expect a potential return of 616.48% based on the average KROS price forecast.
Analyzing the KROS fundamentals
Trailing Twelve Months sales for Keros Therapeutics Inc [NASDAQ:KROS] were 214.71M which represents 254413.25% growth. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -0.05%, Pretax Profit Margin comes in at 0.07%, and Net Profit Margin reading is 0.02%. To continue investigating profitability, this company’s Return on Assets is posted at 0.01, Equity is 0.01 and Total Capital is -0.01. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 13.94 points at the first support level, and at 13.55 for the second support level. However, for the 1st resistance point, the stock is sitting at 14.69, and for the 2nd resistance point, it is at 15.06.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Keros Therapeutics Inc [NASDAQ:KROS] is 19.29. Further, the Quick Ratio stands at 19.29, while the Cash Ratio is 18.3. Considering the valuation of this stock, the price to sales ratio is 2.71, the price to book ratio is 0.80.
Transactions by insiders
Recent insider trading involved ADAR1 Capital Management, LLC, 10% Owner, that happened on Apr 09 ’25 when 0.93 million shares were purchased. Director, GORDON CARL L completed a deal on Aug 13 ’24 to sell 0.25 million shares. Meanwhile, Director ORBIMED ADVISORS LLC sold 0.25 million shares on Aug 13 ’24.
